Kailera Therapeutics Files for US IPO to Fund Obesity Drugs

Kailera Therapeutics Inc. filed for a US initial public offering to help fund the development of its pipeline of obesity drugs.

The clinical-stage biotechnology company had a net loss of $149 million in 2025, compared with a net loss of $219.7 million in the period from its inception on May 8, 2024 to Dec. 31 that year, according to its filing Friday with the US Securities and Exchange Commission.